Jaguar Animal Health, a wholly owned subsidiary of Jaguar Health, Inc., has signed a new long-term crofelemer supply agreement, strengthening the company’s ability to meet increasing demand for one of its flagship plant-derived pharmaceutical ingredients used in veterinary medicine.
The agreement is expected to reinforce Jaguar’s manufacturing and supply chain while supporting the company’s long-term commercial strategy for products targeting gastrointestinal disorders in companion animals and other markets.
The latest development represents another important step in Jaguar’s efforts to ensure a reliable supply of crofelemer as demand for innovative, non-antibiotic therapies continues to grow.
Crofelemer Remains the Foundation of Jaguar’s Product Portfolio
Crofelemer is a proprietary botanical drug derived from the red bark sap of the Croton lechleri tree, commonly known as “Dragon’s Blood,” which is native to South America.
Unlike antibiotics, crofelemer works by regulating chloride and water secretion in the intestines, helping control diarrhea without directly affecting the gut microbiome.
This unique mechanism has made crofelemer an important therapeutic option for managing gastrointestinal disorders in both veterinary and human medicine.
Supporting Companion Animal Healthcare
Jaguar Animal Health has focused much of its veterinary business on developing therapies for companion animals, particularly dogs experiencing acute or chronic diarrhea.
Digestive disorders remain one of the most common reasons pet owners seek veterinary care. Veterinary professionals increasingly emphasize treatments that support intestinal function while minimizing unnecessary antibiotic use.
By securing a dependable crofelemer supply, Jaguar aims to maintain product availability for veterinarians while supporting future commercial expansion.
Strengthening Manufacturing Resilience
Reliable sourcing of pharmaceutical ingredients has become increasingly important across the global animal health industry.
Supply chain disruptions experienced during recent years have highlighted the need for long-term agreements that provide manufacturers with stable access to critical raw materials.
The new crofelemer supply agreement is expected to:
-
Improve manufacturing continuity
-
Support future production planning
-
Reduce supply chain risks
-
Strengthen commercial readiness
-
Enable long-term market expansion
For biotechnology companies with specialized products, dependable ingredient supply is often as important as successful clinical development.
Growing Interest in Plant-Based Veterinary Medicines
Crofelemer is one of the few plant-derived prescription pharmaceutical ingredients used in modern veterinary medicine. Interest in botanical therapeutics continues to increase as researchers explore novel mechanisms that complement conventional drug therapies.
Unlike antimicrobial drugs, crofelemer helps manage fluid loss through a non-antibiotic mechanism, supporting broader industry efforts to promote responsible antimicrobial stewardship.
This approach aligns with growing global initiatives aimed at reducing unnecessary antibiotic exposure in both companion animals and livestock.
Expanding Commercial Opportunities
The agreement comes as Jaguar continues pursuing opportunities to expand crofelemer-based products into additional veterinary and human healthcare markets.
The company has previously highlighted the potential for crofelemer across multiple gastrointestinal conditions and continues evaluating new commercial applications through ongoing research and development.
A secure ingredient supply provides greater confidence for future product launches, regulatory activities and market expansion.
Why This Matters for the Animal Health Industry
The new supply agreement demonstrates how pharmaceutical companies are placing greater emphasis on supply chain resilience alongside scientific innovation.
For veterinary medicine manufacturers, uninterrupted access to specialized active ingredients is essential to maintaining product availability and supporting veterinarians who rely on consistent treatment options.
As demand for innovative gastrointestinal therapies continues to grow, companies with secure manufacturing partnerships and reliable ingredient sourcing are likely to be better positioned to meet future market needs.
Industry Outlook
The global companion animal healthcare market continues to expand as pet ownership increases and owners seek more advanced treatment options for chronic and acute diseases.
Gastrointestinal disorders remain among the leading causes of veterinary consultations, creating sustained demand for safe and effective therapies.
With its new crofelemer supply agreement, Jaguar Animal Health has strengthened an important component of its long-term business strategy, supporting future product availability while reinforcing confidence in its manufacturing network.
As the animal health industry continues investing in innovative therapeutics and resilient supply chains, strategic agreements like this are expected to play an increasingly important role in ensuring reliable access to veterinary medicines worldwide.
Key Highlights
-
Jaguar Animal Health has signed a new long-term crofelemer supply agreement to strengthen its manufacturing and supply chain.
-
The agreement is designed to support continued production and commercial availability of crofelemer-based products.
-
Crofelemer is a plant-derived pharmaceutical ingredient used to manage gastrointestinal disorders through a non-antibiotic mechanism.
-
The agreement supports Jaguar’s long-term growth strategy in both veterinary and human healthcare.
-
Strengthening ingredient supply enhances manufacturing resilience, product availability and future market expansion amid growing demand for innovative companion animal therapies.
